PEG-proteins: Reaction engineering and separation issues

被引:184
作者
Fee, CJ
Van Alstine, JA
机构
[1] Univ Waikato, Dept Mat & Proc Engn, Hamilton 2020, New Zealand
[2] GE Healthcare, Prot Separat, S-75184 Uppsala, Sweden
关键词
PEGylation; proteins; biochemical engineering; separations; reaction engineering; chromatography;
D O I
10.1016/j.ces.2005.04.040
中图分类号
TQ [化学工业];
学科分类号
0817 ;
摘要
Poly(ethylene glycol)-conjugated (or PEGylated) proteins are an increasingly important class of therapeutic proteins that offer improved in vivo circulation half lives over their corresponding native forms. Their production involves covalent attachment of one or more poly(ethylene glycol) molecules to a native protein, followed by purification. Because of the extremely high costs involved in producing native therapeutic proteins it is important that subsequent PEGylation processes are as efficient as possible. In this paper, reaction engineering and purification issues for PEGylated proteins are reviewed. Paramount considerations for PEGylation reactions are specificity with respect to the conjugation site and overall yield. Batch PEGylation reaction methods are discussed, along with innovative methods using packed bed or "on-column" approaches to improve specificity and yield. Purification methods are currently dominated by ion exchange and size exclusion chromatography. Other methods in common use for protein separations, including hydrophobic interaction chromatography, affinity chromatography and membrane separations, are rarely used in PEGylated protein purification schemes. A better understanding of the effects of PEGylation on the physicochemical properties of proteins (isoelectric point, surface charge density and distribution, molecular size and relative hydrophobicity) and interactions between PEGylated proteins and surfaces is needed for the future development of optimal purification processes and media. (c) 2005 Published by Elsevier Ltd.
引用
收藏
页码:924 / 939
页数:16
相关论文
共 93 条
[11]   MODIFICATION OF CD4 IMMUNOADHESIN WITH MONOMETHOXYPOLY(ETHYLENE GLYCOL) ALDEHYDE VIA REDUCTIVE ALKYLATION [J].
CHAMOW, SM ;
KOGAN, TP ;
VENUTI, M ;
GADEK, T ;
HARRIS, RJ ;
PEERS, DH ;
MORDENTI, J ;
SHAK, S ;
ASHKENAZI, A .
BIOCONJUGATE CHEMISTRY, 1994, 5 (02) :133-140
[12]   Therapeutic antibody fragments with prolonged in vivo half-lives [J].
Chapman, AP ;
Antoniw, P ;
Spitali, M ;
West, S ;
Stephens, S ;
King, DJ .
NATURE BIOTECHNOLOGY, 1999, 17 (08) :780-783
[13]   PEGylated antibodies and antibody fragments for improved therapy: a review [J].
Chapman, AP .
ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (04) :531-545
[14]   Enhancement of pH-stability of a low molecular mass endoglucanase from Fusarium oxysporum by protein pegylation [J].
Christakopoulos, P ;
Kourentzi, E ;
Hatzinikolaou, DG ;
Claeyssens, M ;
Kekos, D ;
Macris, BJ .
CARBOHYDRATE RESEARCH, 1998, 314 (1-2) :95-99
[15]  
CLARK R, 1996, J BIOL CHEM, V271, P969
[16]   Analytical partitioning of poly(ethylene glycol)-modified proteins [J].
Delgado, C ;
Malmsten, M ;
VanAlstine, JM .
JOURNAL OF CHROMATOGRAPHY B, 1997, 692 (02) :263-272
[17]   Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases [J].
Edwards, CK ;
Martin, SW ;
Seely, J ;
Kinstler, O ;
Buckel, S ;
Bendele, AM ;
Cosenza, ME ;
Feige, U ;
Kohno, T .
ADVANCED DRUG DELIVERY REVIEWS, 2003, 55 (10) :1315-1336
[18]   PEGylation of growth hormone-releasing hormone (GRF) analogues [J].
Esposito, P ;
Barbero, L ;
Caccia, P ;
Caliceti, P ;
D'Antonio, M ;
Piquet, G ;
Veronese, FM .
ADVANCED DRUG DELIVERY REVIEWS, 2003, 55 (10) :1279-1291
[19]   Prediction of the viscosity radius and the size exclusion chromatography behavior of PEGylated proteins [J].
Fee, CJ ;
Van Alstine, JM .
BIOCONJUGATE CHEMISTRY, 2004, 15 (06) :1304-1313
[20]   Size-exclusion reaction chromatography (SERC): a new technique for protein PEGylation [J].
Fee, CJ .
BIOTECHNOLOGY AND BIOENGINEERING, 2003, 82 (02) :200-206